反応式
CC(C)(C)OC(=O)N1C[C@@H]2C[C@H]1CN2.FC(F)(F)c1cccc(Br)c1>C1COCCO1.CC(C)(C)[O-].O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.[Na+].[Pd].[Pd].c1ccc(P(c2ccccc2)c2ccc3ccccc3c2-c2c(P(c3ccccc3)c3ccccc3)ccc3ccccc23)cc1>CC(C)(C)OC(=O)N1CC2CC1CN2c1cccc(C(F)(F)F)c1参加物
反応物 2
生成物 1
試薬・触媒・溶媒 4
反応条件
- 温度
- 150 °C
実験手順
A 50 ml round bottom equipped with stir bar was charged with binap (0.219 g, 0.34 mmol) and TRIS(DIBENZYLIDENEACETONE)DIPALLADIUM(0) (0.132 g, 0.14 mmol) dissolved in dioxane (6 mL). This was degassed and purged with nitrogen and stirred at RT for 10 mins. 1-bromo-3-(trifluoromethyl)benzene (0.301 mL, 2.16 mmol) followed by tert-butyl 2,5-diazabicyclo[2.2.1]heptane-2-carboxylate (0.3 g, 1.44 mmol) and SODIUM TERT-BUTOXIDE (0.570 g, 5.75 mmol) were added, and the reaction was stirred at 180 °C for 5 min (see notes). The solution was filtered trough celite, diluted with EtOAc and washed with saturated NaHCO3 solution. The aqueous phase was extracted with EtOAc (3X20mL), combined, dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. The crude material was loaded on a Snap KP-SIL 25g column and purified on a Biotage SP4 instrument, eluting with 10% to 35% ethyl acetate in heptane to provide tert-butyl 5-(3-(trifluoromethyl)phenyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate (0.489 g, 99 %) as an oil.
出典と根拠
- ORDレコード
- ord-4b267760e4484094b4eaffe00a0fdfde
- 出典データセット
- 750 AstraZeneca ELN dataset
- 元リンク
- 出典を表示
関連ノート
読み込み中…